60%+ returns in 2025: Here’s how AI-powered stock investing has changed the game
Investing.com - RBC Capital has raised its price target on Viridian Therapeutic (NASDAQ:VRDN) to $45.00 from $41.00 while maintaining an Outperform rating. The stock has shown remarkable momentum with a 103% price return over the past six months and is currently trading at $24.42, according to InvestingPro data.
The firm cited Viridian’s recent submission of a Biologics License Application (BLA) for its veli’ treatment in late October, which occurred despite FDA volatility and government shutdown concerns. The treatment has Breakthrough Therapy Designation, potentially enabling commercial launch as early as mid-2026.
Viridian has narrowed timelines for pivotal studies of its next-generation subcutaneous ’003 treatment, with readouts expected in Q1 and Q2 2026 for active and chronic Thyroid Eye Disease (TED), respectively. The company remains on track for a BLA filing by year-end 2026.
RBC Capital noted that recent financing activities have strengthened Viridian’s cash position to $888 million, which the company expects will fund operations through to profitability. These financing deals include a $70 million upfront Japan licensing agreement, $55 million from DRI royalty financing, a $289 million follow-on offering, and access to a $300 million credit facility. InvestingPro data confirms Viridian holds more cash than debt with an impressive current ratio of 11.01, though the company is not yet profitable with an EBITDA of -$371.1 million for the last twelve months.
The firm believes veli’ offers meaningful differentiation from standard-of-care treatment Tepezza and suggests the potential for 50% market share based on key opinion leader conversations. For deeper analysis of Viridian’s financial health and growth prospects, check out the comprehensive Pro Research Report available on InvestingPro, which covers this and over 1,400 other US equities with expert insights.
In other recent news, Viridian Therapeutics has made significant strides with the submission of a Biologics License Application (BLA) to the U.S. Food and Drug Administration for veligrotug, aimed at treating thyroid eye disease. This submission, completed in late October, is a pivotal step for the company, and the FDA is expected to decide on accepting the application within 60 days. Additionally, Viridian has priced a public offering of 11,425,000 shares of its common stock at $22.00 per share, which is anticipated to generate approximately $251.35 million in gross proceeds. This offering includes an option for underwriters to purchase an additional 1,713,750 shares.
Further developments include Viridian’s launch of a public offering of common stock and Series B non-voting convertible preferred stock, with plans to use the proceeds to fund commercial launch activities and other corporate purposes. Analyst firm Stifel has raised its price target for Viridian Therapeutics to $48.00, maintaining a Buy rating, in light of these recent activities. Meanwhile, H.C. Wainwright has reaffirmed its Buy rating and $34.00 price target following Viridian’s royalty financing agreement with DRI Healthcare Acquisitions LP. This agreement provides up to $300 million in financing, with $55 million available upfront and additional funds contingent on certain milestones.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.